Research and Markets (http://www.researchandmarkets.com/research/xd3gfg/nouriast)
has announced the addition of the "Nouriast
(Parkinson's Disease) - Forecast and Market Analysis to 2022"
report to their offering.
Istradefylline is a first-in-class adenosine A2 receptor inhibitor,
marketed in Japan under the brand name Nouriast by Kyowa Hakko Kirin. It
was approved in Japan for adjunct use with levodopa in advanced-stage
patients with wearing-off in March 2013, and launched in May 2013 (Kyowa
Hakko Kirin, press release, March 25, 2013; Kyowa Hakko Kirin, press
release, May 29, 2013).
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Nouriast (istradefylline)
For more information visit http://www.researchandmarkets.com/research/xd3gfg/nouriast
[ Back To NFVZone's Homepage ]